Key facts
- The STREAM trial randomised 1,880 adults aged 70 or older with at least two chronic conditions and no cardiovascular disease to stop or continue their statin.
- Stopping was non-inferior to continuing for heart attack, ischaemic stroke or death at 2 years.
- Over the full follow-up (up to 4 years), events occurred in 12.7% of those who stopped versus 9.2% of those who continued.
- The results were published in the New England Journal of Medicine and presented at the AHA Scientific Sessions on 7 November 2026.
What happened
Swiss and US researchers led by Nicolas Rodondi randomly assigned older adults who had taken a statin for at least a year for primary prevention to discontinue or continue it. Participants had a mean age of 77.5 years and no history of heart attack, stroke or other established cardiovascular disease.
Why it matters
Many older adults take statins for years, and the benefit of continuing them for primary prevention in later life is uncertain, especially in people who already take many medicines. The trial gives randomised evidence on what happens when they are stopped.
Context
Stopping met the trial’s main safety test at 2 years, but over the longer follow-up rates were higher in the discontinuation group: heart attack 1.6% vs 0.6%, ischaemic stroke 2.2% vs 0.8% and death from any cause 9.8% vs 8%. The trial was open-label, about 14% of participants did not follow their assigned plan, and most follow-up was around 2 years. Commentators stress the result applies only to people without established cardiovascular disease and does not support a blanket recommendation to stop.
What it means for clinicians and students
- Clinicians: deprescribing statins can be considered in selected older adults with multimorbidity, as a shared decision that weighs risks, preferences and life expectancy.
- Patients: do not stop a statin on your own; discuss your personal risk with your doctor.
- Students: note the difference between non-inferiority at a fixed time point and higher event rates over longer follow-up, and why primary and secondary prevention are different questions.
Source: Rodondi N, et al. Discontinuing statins in older adults without cardiovascular disease. New England Journal of Medicine, 7 November 2026 (STREAM trial); reported by HCPLive.
Source: HCPLive (NEJM, STREAM trial)















